Researchers at Leiden University in the Netherlands have identified a specialized enzyme that allows bacteria to survive in environments with very low oxygen [1].
This discovery is significant because it reveals a survival mechanism used by pathogenic bacteria to persist in the body. By understanding how these organisms survive without ample oxygen, scientists can develop new antibiotics designed to block this specific enzymatic process and kill the bacteria [2].
The findings were detailed in a paper published in Science Advances this month [1]. The research team focused on how bacteria maintain viability when oxygen levels drop, a condition often found during infections in human tissues [2].
Researchers said the enzyme acts as a critical tool for bacterial persistence [1]. When the team inhibited this enzyme, the bacteria were unable to survive the low-oxygen conditions and died [2]. This suggests that the enzyme is not merely helpful but essential for survival in such niches.
Developing drugs that target this enzyme could provide a way to treat infections that are otherwise resistant to standard treatments. Because many antibiotics rely on the presence of oxygen or specific metabolic pathways to work, targeting a survival enzyme used in anaerobic or microaerophilic conditions offers a different strategic approach [1].
The team's work in Leiden emphasizes the importance of metabolic flexibility in pathogens [2]. By stripping away the bacteria's ability to adapt to low-oxygen environments, the researchers have opened a potential new avenue for pharmaceutical development [1].
“Inhibiting this enzyme can kill the bacteria, suggesting a new target for antibiotics.”
This research shifts the focus of antibiotic development toward the metabolic vulnerabilities of bacteria. By targeting the mechanisms that allow pathogens to survive in the oxygen-poor environments typical of deep-tissue infections, scientists may be able to eliminate bacteria that previously evaded treatment by entering a dormant or low-metabolic state.
